The Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE) criteria were introduced to fill this gap, offering a molecular imaging-based TNM (miTNM) classification for interpreting PSMA-ligand PET/CT findings. This evidence concerns the gene FOLH1 and Familial prostate cancer.